PH12018501207B1 - Compositions and methods for decreasing tau expression - Google Patents

Compositions and methods for decreasing tau expression

Info

Publication number
PH12018501207B1
PH12018501207B1 PH1/2018/501207A PH12018501207A PH12018501207B1 PH 12018501207 B1 PH12018501207 B1 PH 12018501207B1 PH 12018501207 A PH12018501207 A PH 12018501207A PH 12018501207 B1 PH12018501207 B1 PH 12018501207B1
Authority
PH
Philippines
Prior art keywords
compositions
methods
tau expression
decreasing tau
decreasing
Prior art date
Application number
PH1/2018/501207A
Other languages
English (en)
Other versions
PH12018501207A1 (en
Inventor
Ofengeim Manuela Polydoro
Jan Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PH12018501207A1 publication Critical patent/PH12018501207A1/en
Publication of PH12018501207B1 publication Critical patent/PH12018501207B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2018/501207A 2015-12-21 2016-12-19 Compositions and methods for decreasing tau expression PH12018501207B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270165P 2015-12-21 2015-12-21
PCT/IB2016/057794 WO2017109679A1 (en) 2015-12-21 2016-12-19 Compositions and methods for decreasing tau expression

Publications (2)

Publication Number Publication Date
PH12018501207A1 PH12018501207A1 (en) 2019-02-11
PH12018501207B1 true PH12018501207B1 (en) 2024-02-23

Family

ID=57758674

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2018/501207A PH12018501207B1 (en) 2015-12-21 2016-12-19 Compositions and methods for decreasing tau expression

Country Status (41)

Country Link
US (2) US11473083B2 (enExample)
EP (2) EP3394259B1 (enExample)
JP (4) JP7027328B2 (enExample)
KR (2) KR20250112919A (enExample)
CN (2) CN116218848A (enExample)
AR (1) AR107579A1 (enExample)
AU (2) AU2016376034B2 (enExample)
CA (1) CA3008094A1 (enExample)
CL (3) CL2018001652A1 (enExample)
CO (1) CO2018006297A2 (enExample)
CR (1) CR20200609A (enExample)
CU (1) CU24574B1 (enExample)
DK (1) DK3394259T3 (enExample)
DO (1) DOP2018000151A (enExample)
EA (2) EA202091865A1 (enExample)
EC (1) ECSP18050575A (enExample)
ES (1) ES2984631T3 (enExample)
FI (1) FI3394259T3 (enExample)
HR (1) HRP20240672T1 (enExample)
HU (1) HUE066548T2 (enExample)
IL (3) IL296844B2 (enExample)
JO (2) JOP20200228A1 (enExample)
LT (1) LT3394259T (enExample)
MA (2) MA71468A (enExample)
MX (2) MX2018007726A (enExample)
MY (1) MY191737A (enExample)
NZ (2) NZ743231A (enExample)
PE (2) PE20241069A1 (enExample)
PH (1) PH12018501207B1 (enExample)
PL (1) PL3394259T3 (enExample)
PT (1) PT3394259T (enExample)
RS (1) RS65535B1 (enExample)
RU (1) RU2747734C2 (enExample)
SA (1) SA518391831B1 (enExample)
SG (2) SG11201804704PA (enExample)
SI (1) SI3394259T1 (enExample)
SV (1) SV2018005714A (enExample)
TW (2) TWI787163B (enExample)
UY (1) UY37038A (enExample)
WO (1) WO2017109679A1 (enExample)
ZA (1) ZA201803661B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
CN111868068A (zh) * 2018-03-13 2020-10-30 詹森药业有限公司 用于在tau蛋白病变治疗中使用的经修饰的寡核苷酸
EP3818159A1 (en) 2018-07-03 2021-05-12 F. Hoffmann-La Roche AG Oligonucleotides for modulating tau expression
CA3178304A1 (en) * 2020-03-30 2021-10-07 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
CN117980478A (zh) * 2021-06-16 2024-05-03 艾姆皮瑞克公司 Mtres1相关疾病和病症的治疗
WO2023288111A2 (en) * 2021-07-16 2023-01-19 Aptah Bio, Inc. Polynucleotide compositions and methods for gene expression regulation
EP4608981A1 (en) * 2022-10-25 2025-09-03 Empirico Inc. Gene therapy treatment of mtres1 related diseases and disorders
CN120958129A (zh) * 2023-01-18 2025-11-14 阿普塔生物公司 用于治疗癌症的多核苷酸组合物和方法
WO2024155739A1 (en) * 2023-01-18 2024-07-25 Aptah Bio, Inc. Polynucleotide compositions and methods for treatment of neurodegenerative diseases
AU2024258561A1 (en) * 2023-04-20 2025-10-30 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
US20250283084A1 (en) * 2024-03-08 2025-09-11 Eli Lilly And Company Mapt antisense oligonucleotide
WO2025212467A1 (en) * 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JP2580091B2 (ja) 1990-01-11 1997-02-12 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａ活性および遺伝子発現を検出および変調するための組成物および方法
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US20020052331A1 (en) 1990-08-14 2002-05-02 Brenda Baker Compositions and methods for antisense inhibition of protein translation
EP0911390B1 (en) 1991-12-06 2009-08-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
NZ256974A (en) * 1992-10-05 1997-12-19 Isis Pharmaceuticals Inc Oligonucleotides and compositions thereof for modulating expression of the human ras gene
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
ES2290951T3 (es) 1993-05-11 2008-02-16 The University Of North Carolina At Chapel Hill Oligonucleotidos antisentido que combaten el corte y empalme aberrante y metodos de uso de los mismos.
PL328563A1 (en) 1996-02-14 1999-02-01 Isis Pharmaceuticals Inc Oligonucleotides of modified sugar residues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
ATE293123T1 (de) 1997-09-12 2005-04-15 Exiqon As Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
CA2330944A1 (en) 1998-05-01 1999-11-11 Mayo Foundation For Medical Education And Research Pathogeniv tau mutations
TW200728465A (en) * 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
DK1152009T4 (en) 1999-02-12 2017-12-11 Daiichi Sankyo Co Ltd HIS UNKNOWN NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGS
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6350868B1 (en) 1999-04-26 2002-02-26 University Of North Carolina At Chapel Hill Antisense human fucosyltransferase sequences and methods of use thereof
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CN101284873A (zh) * 1999-06-30 2008-10-15 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
EP1248518A2 (en) 2000-01-21 2002-10-16 PHARMACIA & UPJOHN COMPANY Transgenic mouse model of human neurodegenerative disease
US20020045577A1 (en) * 2000-02-28 2002-04-18 Decode Genetics Human schizophrenia gene
WO2002055681A2 (en) 2001-01-11 2002-07-18 Bayer Ag Regulation of human tau-tubulin kinase
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
WO2004003134A2 (en) 2002-06-26 2004-01-08 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
US7696345B2 (en) 2002-11-05 2010-04-13 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7906326B2 (en) 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
NZ545360A (en) 2003-08-28 2009-06-26 Novartis Ag Interfering RNA duplex having blunt-ends and 3'-modifications
US20070106066A1 (en) 2003-10-28 2007-05-10 Alexander Cherkasky Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
EP1766010B1 (en) 2004-06-28 2011-02-16 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US7312035B2 (en) 2004-09-03 2007-12-25 Affymetrix, Inc. Methods of genetic analysis of yeast
JP5921052B2 (ja) 2004-12-03 2016-05-24 ロード アイランド ホスピタル アルツハイマー病の検査
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
WO2007028065A2 (en) 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2008002620A2 (en) 2006-06-27 2008-01-03 University Of Virginia Patent Foundation Cell model for alzheimer's disease pathology
JP2010509923A (ja) 2006-11-23 2010-04-02 ミルクス セラピューティクス アンパーツゼルスカブ 標的ｒｎａの活性を変化させるためのオリゴヌクレオチド
WO2008124066A1 (en) 2007-04-05 2008-10-16 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
BR112012011195B1 (pt) 2009-11-12 2024-02-15 The University Of Western Australia Oligonucleotídeo antissentido, composição farmacêutica e uso de uma composição farmacêutica
US20150018223A1 (en) 2010-01-28 2015-01-15 University Of Massachusetts Lowell Methods of diagnosing tau-associated neurodegenerative diseases
WO2011117353A1 (en) 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2643341A4 (en) 2010-11-23 2014-08-27 Mirrx Therapeutics As Oligonucleotides for modulating a TARGET RNA activity
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
EP3495497B1 (en) * 2011-04-28 2021-03-24 Life Technologies Corporation Methods and compositions for multiplex pcr
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
BR112014030098A2 (pt) 2012-06-04 2017-07-25 Irm Llc métodos de rotulagem específica de sítio e moléculas produzidas pelos mesmos
CN104936977B (zh) 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
EP3885439A1 (en) 2012-12-20 2021-09-29 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
EP3633035A1 (en) 2013-03-14 2020-04-08 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
EP3766974A1 (en) 2013-03-14 2021-01-20 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
KR20220061280A (ko) 2013-03-14 2022-05-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
WO2014201306A1 (en) 2013-06-12 2014-12-18 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
TW202246503A (zh) * 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015068075A2 (en) 2013-10-24 2015-05-14 Institut National De La Sante Et De La Recherche Medicale Detection of tau
EP3736334A1 (en) * 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
US20170211064A1 (en) 2014-07-29 2017-07-27 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
EP3253871A1 (en) 2015-02-04 2017-12-13 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
HK1248276A1 (zh) 2015-02-04 2018-10-12 F. Hoffmann-La Roche Ag Tau 反义低聚物及其用途
JP6772156B2 (ja) 2015-02-04 2020-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 治療用分子を選択する方法
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases

Also Published As

Publication number Publication date
US11473083B2 (en) 2022-10-18
UY37038A (es) 2017-07-31
MY191737A (en) 2022-07-13
CL2018001652A1 (es) 2018-08-10
IL305866A (en) 2023-11-01
CO2018006297A2 (es) 2018-07-10
SV2018005714A (es) 2018-09-10
US20170175116A1 (en) 2017-06-22
MX2023008211A (es) 2023-07-18
US20220411796A1 (en) 2022-12-29
JO3790B1 (ar) 2021-01-31
NZ783034A (en) 2025-07-25
MX2018007726A (es) 2018-08-15
CN109072237B (zh) 2022-12-16
SG11201804704PA (en) 2018-07-30
RU2018126545A3 (enExample) 2020-10-12
MA44426B1 (fr) 2024-05-31
DOP2018000151A (es) 2018-09-15
IL296844A (en) 2022-11-01
FI3394259T3 (fi) 2024-05-24
DK3394259T3 (da) 2024-05-27
JP2019500428A (ja) 2019-01-10
EA201891468A1 (ru) 2018-12-28
RU2021112980A (ru) 2021-05-28
EP3394259A1 (en) 2018-10-31
IL296844B1 (en) 2023-12-01
PH12018501207A1 (en) 2019-02-11
HK1254822A1 (en) 2019-07-26
RU2021112980A3 (enExample) 2021-12-28
CL2019000149A1 (es) 2019-06-07
HRP20240672T1 (hr) 2024-08-16
NZ743231A (en) 2025-07-25
AU2020267282B2 (en) 2023-05-18
EP4406541A2 (en) 2024-07-31
ES2984631T3 (es) 2024-10-30
IL305866B2 (en) 2024-12-01
PE20181448A1 (es) 2018-09-12
CL2019003420A1 (es) 2020-05-15
AU2016376034A1 (en) 2018-07-05
LT3394259T (lt) 2024-06-10
TW201733597A (zh) 2017-10-01
AR107579A1 (es) 2018-05-16
BR112018012304A2 (pt) 2019-02-05
KR102834468B1 (ko) 2025-07-15
PT3394259T (pt) 2024-05-20
PL3394259T3 (pl) 2024-07-22
RU2747734C2 (ru) 2021-05-13
JP2025026976A (ja) 2025-02-26
TWI787163B (zh) 2022-12-21
KR20250112919A (ko) 2025-07-24
ZA201803661B (en) 2024-08-28
JP2021118732A (ja) 2021-08-12
SI3394259T1 (sl) 2024-07-31
CR20200609A (es) 2021-02-17
JP7027328B2 (ja) 2022-03-01
ECSP18050575A (es) 2018-07-31
PE20241069A1 (es) 2024-05-13
KR20180089517A (ko) 2018-08-08
EP4406541A3 (en) 2024-10-16
AU2020267282A1 (en) 2020-12-10
JP2022065096A (ja) 2022-04-26
SG10201913434PA (en) 2020-03-30
CN109072237A (zh) 2018-12-21
TWI834177B (zh) 2024-03-01
MA71468A (fr) 2025-04-30
CA3008094A1 (en) 2017-06-29
EA036417B1 (ru) 2020-11-09
CN116218848A (zh) 2023-06-06
SA518391831B1 (ar) 2022-08-16
IL260124A (en) 2018-07-31
JOP20200228A1 (ar) 2017-06-16
JP7594557B2 (ja) 2024-12-04
IL305866B1 (en) 2024-08-01
AU2016376034B2 (en) 2020-12-03
RU2018126545A (ru) 2020-01-23
IL296844B2 (en) 2024-04-01
WO2017109679A1 (en) 2017-06-29
CU20180065A7 (es) 2018-11-06
CU24574B1 (es) 2022-01-13
HUE066548T2 (hu) 2024-08-28
RS65535B1 (sr) 2024-06-28
TW202311530A (zh) 2023-03-16
EA202091865A1 (ru) 2021-01-29
EP3394259B1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
ZA201803661B (en) Compositions and methods for decreasing tau expression
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
SG11201706755SA (en) Methods and compositions for treating genetic eye diseases
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
CA3149282C (en) COMPOSITIONS TO MODULATE THE EXPRESSION OF TAU
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
EP3238736A4 (en) Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
EP3148575A4 (en) Methods and compositions for treating allergy and inflammatory diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
IL265831A (en) Preparations and methods for protein expression and administration
PH12017500602A1 (en) Methods for treating ocular conditions
EA201791937A1 (ru) Противовоспалительные полипептиды
EP3364965A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3672583A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
HK40009796A (en) Silk-derived protein for treating inflammation
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis